167 related articles for article (PubMed ID: 37131012)
1. Identifying Safety Subgroups at Risk: Assessing the Agreement Between Statistical Alerting and Patient Subgroup Risk.
Mahaux O; Powell G; Haguinet F; Sobczak P; Saini N; Barry A; Mustafa A; Bate A
Drug Saf; 2023 Jun; 46(6):601-614. PubMed ID: 37131012
[TBL] [Abstract][Full Text] [Related]
2. Risk Factor Considerations in Statistical Signal Detection: Using Subgroup Disproportionality to Uncover Risk Groups for Adverse Drug Reactions in VigiBase.
Sandberg L; Taavola H; Aoki Y; Chandler R; Norén GN
Drug Saf; 2020 Oct; 43(10):999-1009. PubMed ID: 32564242
[TBL] [Abstract][Full Text] [Related]
3. Complementing the US Food and Drug Administration Adverse Event Reporting System With Adverse Drug Reaction Reporting From Social Media: Comparative Analysis.
Zhou Z; Hultgren KE
JMIR Public Health Surveill; 2020 Sep; 6(3):e19266. PubMed ID: 32996889
[TBL] [Abstract][Full Text] [Related]
4. A Pharmacovigilance Study of Adverse Drug Reactions Reported for Cardiovascular Disease Medications Approved Between 2012 and 2017 in the United States Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
Patel NM; Stottlemyer BA; Gray MP; Boyce RD; Kane-Gill SL
Cardiovasc Drugs Ther; 2022 Apr; 36(2):309-322. PubMed ID: 33599896
[TBL] [Abstract][Full Text] [Related]
5. Novel Adverse Events of Iloperidone: A Disproportionality Analysis in US Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
Subeesh V; Maheswari E; Singh H; Beulah TE; Swaroop AM
Curr Drug Saf; 2019; 14(1):21-26. PubMed ID: 30362421
[TBL] [Abstract][Full Text] [Related]
6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
7. Data mining for adverse drug reaction signals of daptomycin based on real-world data: a disproportionality analysis of the US Food and Drug Administration adverse event reporting system.
Chen JJ; Huo XC; Wang SX; Wang F; Zhao Q
Int J Clin Pharm; 2022 Dec; 44(6):1351-1360. PubMed ID: 36178607
[TBL] [Abstract][Full Text] [Related]
8. Profiling cumulative proportional reporting ratios of drug-induced liver injury in the FDA Adverse Event Reporting System (FAERS) database.
Brinker AD; Lyndly J; Tonning J; Moeny D; Levine JG; Avigan MI
Drug Saf; 2013 Dec; 36(12):1169-78. PubMed ID: 24178291
[TBL] [Abstract][Full Text] [Related]
9. A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib.
Peng L; Xiao K; Ottaviani S; Stebbing J; Wang YJ
Expert Opin Drug Saf; 2020 Nov; 19(11):1505-1511. PubMed ID: 32693646
[TBL] [Abstract][Full Text] [Related]
10. Adverse Drug Reaction Risk Measures: A Comparison of Estimates from Drug Surveillance and Randomised Trials.
Beau-Lejdstrom R; Crook S; Spanu A; Yu T; Puhan MA
Pharmaceut Med; 2019 Aug; 33(4):331-339. PubMed ID: 31933187
[TBL] [Abstract][Full Text] [Related]
11. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
Welch HK; Kellum JA; Kane-Gill SL
Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
[TBL] [Abstract][Full Text] [Related]
12. Use of Disproportionality Analysis to Identify Previously Unknown Drug-Associated Causes of Cardiac Arrhythmias Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
Moreland-Head LN; Coons JC; Seybert AL; Gray MP; Kane-Gill SL
J Cardiovasc Pharmacol Ther; 2021 Jul; 26(4):341-348. PubMed ID: 33403858
[TBL] [Abstract][Full Text] [Related]
13. A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib.
Yin Y; Shu Y; Zhu J; Li F; Li J
Sci Rep; 2022 Nov; 12(1):19555. PubMed ID: 36380085
[TBL] [Abstract][Full Text] [Related]
14. Adverse drug reaction risks obtained from meta-analyses and pharmacovigilance disproportionality analyses are correlated in most cases.
Khouri C; Petit C; Tod M; Lepelley M; Revol B; Roustit M; Cracowski JL
J Clin Epidemiol; 2021 Jun; 134():14-21. PubMed ID: 33508405
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
[TBL] [Abstract][Full Text] [Related]
16. Disproportionality Analysis of Lenvatinib-Caused Gastrointestinal Perforation in Cancer Patients: A Pharmacovigilance Analysis Based on the US Food and Drug Administration Adverse Event Reporting System.
Zhou J; Wei Z; Zheng Y; Xie H; Cao W; Cai X; Huang J; Wu X
J Clin Pharmacol; 2023 Oct; 63(10):1133-1140. PubMed ID: 37474123
[TBL] [Abstract][Full Text] [Related]
17. Safety concerns reported by consumers, manufacturers and healthcare professionals: A detailed evaluation of opioid-related adverse drug reactions in the FDA database over 15 years.
Andreaggi CA; Novak EA; Mirabile ME; Sampathkumar S; Gray MP; He M; Kane-Gill SL
Pharmacoepidemiol Drug Saf; 2020 Dec; 29(12):1627-1635. PubMed ID: 32851782
[TBL] [Abstract][Full Text] [Related]
18. Letter to the editor concerning the article: 'Potential cerebrovascular accident signal for risankizumab: A disproportionality analysis of the FDA adverse event reporting system (FAERS)'.
Sinvhal R; Krueger WS; Kilpatrick RD; Coppola D
Br J Clin Pharmacol; 2023 Aug; 89(8):2639-2641. PubMed ID: 37114281
[No Abstract] [Full Text] [Related]
19. Comparison of Online Patient Reviews and National Pharmacovigilance Data for Tramadol-Related Adverse Events: Comparative Observational Study.
Park S; Choi SH; Song YK; Kwon JW
JMIR Public Health Surveill; 2022 Jan; 8(1):e33311. PubMed ID: 34982723
[TBL] [Abstract][Full Text] [Related]
20. Lessons learned on the design and the conduct of Post-Authorization Safety Studies: review of 3 years of PRAC oversight.
Engel P; Almas MF; De Bruin ML; Starzyk K; Blackburn S; Dreyer NA
Br J Clin Pharmacol; 2017 Apr; 83(4):884-893. PubMed ID: 27780289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
